Clinical Trials Logo
  1. Home
  2. Angioedema
  3. NCT06096077

Evaluation of Tranexamic Acid for Angiotensin-converting Enzyme Inhibitor-induced Angioedema in the Emergency Department

Angioedema Clinical Trial

Official title:
Evaluation of Tranexamic Acid for Angiotensin-converting Enzyme Inhibitor-induced Angioedema in the Emergency Department

Clinical Trial Summary

Angiotensin-converting enzyme inhibitor ACEi induced angioedema ACEi-AE is defined as physical swelling of the deep skin layers or mucous membranes due to increased vascular permeability and leakage of fluid into the interstitial space caused while taking an ACEi

Clinical Trial Description

Angiotensin-converting enzyme inhibitor ACEi induced angioedema ACEi-AE most commonly affects the lips, mouth, face, upper airway, and less commonly the gastrointestinal tract. This condition may lead to life-threatening airway compromise which would require emergent intubation. Currently, strong evidence is lacking to help guide management of ACEi-AE in the emergency department (ED). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06096077
Study type Observational
Source Methodist Health System
Contact
Status Completed
Phase
Start date November 30, 2022
Completion date August 23, 2023
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT00163839 - The Efficacy of a Pseudoallergen-Free Diet in the Treatment of Chronic Idiopathic Urticaria and/or Angioedema N/A
Recruiting NCT04597944 - Lanadelumab in Bradykinin Angioedema
Recruiting NCT03845946 - CLOUD-R HAE REGISTRY
Completed NCT00876369 - Vitamin D Levels in Subjects With Chronic Urticaria and Angioedema
Completed NCT02833675 - Determination of Specific Biomarkers of Angioneurotic Crisis N/A
Completed NCT00125541 - C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema Phase 2/Phase 3
Completed NCT01371877 - The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment N/A
Completed NCT04206605 - A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) Phase 3
Unknown status NCT01036659 - Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Phase 2
Recruiting NCT05578417 - A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada
Recruiting NCT05936567 - Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Phase 2
Recruiting NCT04334031 - Deployment o the Multidisciplinary Prospective Cohort Imminent N/A
Completed NCT03240991 - Study of Clinical, Biological Characteristics and Quality of Life of Patients With Hereditary or Acquired Non Drug-induced Bradykinin-mediated Angioedema, Monitored in Besançon's Partner Site Reference Center for Studies of Kinin-mediated Angioedema (CREAK)
Completed NCT01723072 - Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy Phase 3
Completed NCT00385372 - Significance of an Elimination and Provocation Diet in Patients With Chronic Urticaria N/A
Completed NCT00004694 - Study of Heparin Prophylaxis of Hereditary Angioedema Exacerbations N/A
Not yet recruiting NCT06210698 - Angioedema Biomarker Research Study
Terminated NCT04128371 - Mepolizumab in Episodic Angioedema With Eosinophilia Phase 2
Completed NCT04444895 - A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor Phase 3
Completed NCT00125151 - C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema Phase 3